IN2014DN10672A - - Google Patents

Info

Publication number
IN2014DN10672A
IN2014DN10672A IN10672DEN2014A IN2014DN10672A IN 2014DN10672 A IN2014DN10672 A IN 2014DN10672A IN 10672DEN2014 A IN10672DEN2014 A IN 10672DEN2014A IN 2014DN10672 A IN2014DN10672 A IN 2014DN10672A
Authority
IN
India
Prior art keywords
composition
lactic
weeks
drug
glycolic acid
Prior art date
Application number
Other languages
English (en)
Inventor
Aduriz Ibon Gutierro
Rodríguez Guillermo Franco
Original Assignee
Farmacéuticos Rovi S A Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46147376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN10672(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Farmacéuticos Rovi S A Lab filed Critical Farmacéuticos Rovi S A Lab
Publication of IN2014DN10672A publication Critical patent/IN2014DN10672A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN10672DEN2014 2012-05-31 2013-05-31 IN2014DN10672A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12170362.3A EP2529756B1 (fr) 2011-05-31 2012-05-31 Formulation d'implant de rispéridone et/ou de palipéridone
PCT/EP2013/061320 WO2013178812A1 (fr) 2012-05-31 2013-05-31 Formulation pour implant contenant de la rispéridone et/ou de la palipéridone

Publications (1)

Publication Number Publication Date
IN2014DN10672A true IN2014DN10672A (fr) 2015-08-28

Family

ID=46147376

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10672DEN2014 IN2014DN10672A (fr) 2012-05-31 2013-05-31

Country Status (32)

Country Link
EP (2) EP2529756B1 (fr)
JP (1) JP6367795B2 (fr)
KR (1) KR101880716B1 (fr)
CN (1) CN104363923A (fr)
AU (1) AU2013269547B2 (fr)
BR (1) BR112014029209A2 (fr)
CA (1) CA2874765C (fr)
CL (1) CL2014003216A1 (fr)
CO (1) CO7160108A2 (fr)
CY (1) CY1124369T1 (fr)
DK (2) DK2529756T3 (fr)
EA (1) EA031819B1 (fr)
ES (2) ES2878112T3 (fr)
FI (1) FI2854858T3 (fr)
HR (2) HRP20260301T1 (fr)
IL (1) IL235849B (fr)
IN (1) IN2014DN10672A (fr)
LT (2) LT2529756T (fr)
MA (1) MA37664B1 (fr)
MX (1) MX374955B (fr)
MY (1) MY174999A (fr)
NZ (1) NZ703321A (fr)
PH (1) PH12014502667B1 (fr)
PL (2) PL2529756T3 (fr)
PT (2) PT2529756T (fr)
RS (1) RS62059B1 (fr)
SG (1) SG11201407961WA (fr)
SI (2) SI2529756T1 (fr)
SM (1) SMT202100448T1 (fr)
UA (1) UA119430C2 (fr)
WO (1) WO2013178812A1 (fr)
ZA (1) ZA201409299B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2152315B1 (fr) 2007-05-25 2016-01-06 Indivior UK Limited Formulations d'administration prolongée de composés de rispéridone
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
EP2529756B1 (fr) * 2011-05-31 2021-05-19 Laboratorios Farmaceuticos Rovi, S.A. Formulation d'implant de rispéridone et/ou de palipéridone
EP2394664B1 (fr) 2010-05-31 2016-06-01 Laboratorios Farmaceuticos Rovi, S.A. Compositions pour implants biodégradables in situ injectables
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
SI2394663T1 (sl) 2010-05-31 2022-02-28 Laboratorios Farmaceuticos Rovi, S.A. Sestave za injicirane biološko razgradljive vsadke in situ
SI2529757T1 (sl) * 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata
WO2014164754A1 (fr) 2013-03-11 2014-10-09 Durect Corporation Composition injectable à libération contrôlée comprenant un véhicule liquide à haute viscosité
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
CN104922085B (zh) * 2015-06-01 2016-10-26 湖南赛沃药业有限公司 一种利培酮植入剂及其制备方法
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
CA3087238A1 (fr) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Dispositif implantable pour la liberation prolongee d'un compose medicamenteux macromoleculaire
CN111989068B (zh) 2018-05-24 2024-10-25 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
EP3803866A4 (fr) 2018-05-24 2022-03-16 Nureva Inc. Procédé, appareil et supports lisibles par ordinateur pour gérer des sources sonores semi-constantes (persistantes) dans des zones de capture/foyer de microphones
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
EP4329734A4 (fr) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Dispositif implantable pour la libération prolongée d'un composé médicamenteux macromoléculaire
US12594236B2 (en) 2021-07-16 2026-04-07 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物
WO2023233051A1 (fr) 2022-05-18 2023-12-07 Laboratorios Farmacéuticos Rovi, S.A. Compositions injectables à libération prolongée destinées à être utilisées dans le cadre du traitement par rispéridone en association avec des inhibiteurs de l'enzyme cyp2d6

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE288270T1 (de) 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
EP1660039B1 (fr) * 2003-07-18 2016-09-28 Oakwood Laboratories L.L.C. Prevention de reduction de poids moleculaire du polymere, de formation d'impuretes et de gelification dans des compositions polymeres
JP2008509144A (ja) 2004-08-04 2008-03-27 アルザ・コーポレーシヨン 上昇するゼロ次放出パターンを示す持続薬剤放出組成物、そのような組成物を製造する方法
US8314110B2 (en) 2007-04-19 2012-11-20 Youxin Li Compounds for treating mental disorders, and preparation and uses thereof
CN101677952B (zh) * 2007-05-18 2012-12-05 杜雷科特公司 改进的贮库制剂
EP2152315B1 (fr) * 2007-05-25 2016-01-06 Indivior UK Limited Formulations d'administration prolongée de composés de rispéridone
WO2009015828A1 (fr) 2007-07-27 2009-02-05 Synthon B.V. Dérivés de palipéridone
CA2655335C (fr) 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Posologie associee aux esters de paliperidone injectables a action prolongee
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
EP2394664B1 (fr) * 2010-05-31 2016-06-01 Laboratorios Farmaceuticos Rovi, S.A. Compositions pour implants biodégradables in situ injectables
EP2529756B1 (fr) * 2011-05-31 2021-05-19 Laboratorios Farmaceuticos Rovi, S.A. Formulation d'implant de rispéridone et/ou de palipéridone
SI2394663T1 (sl) * 2010-05-31 2022-02-28 Laboratorios Farmaceuticos Rovi, S.A. Sestave za injicirane biološko razgradljive vsadke in situ
SI2529757T1 (sl) * 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata

Also Published As

Publication number Publication date
CY1124369T1 (el) 2022-07-22
LT2529756T (lt) 2021-07-26
SI2854858T1 (sl) 2026-04-30
EP2529756A2 (fr) 2012-12-05
CN104363923A (zh) 2015-02-18
EP2529756A3 (fr) 2013-08-07
ZA201409299B (en) 2015-12-23
ES3064200T3 (en) 2026-04-23
FI2854858T3 (fi) 2026-03-03
CA2874765C (fr) 2020-06-02
CO7160108A2 (es) 2015-01-15
PL2529756T3 (pl) 2021-11-15
SG11201407961WA (en) 2014-12-30
JP6367795B2 (ja) 2018-08-01
MX374955B (es) 2025-03-06
JP2015518036A (ja) 2015-06-25
UA119430C2 (uk) 2019-06-25
KR101880716B1 (ko) 2018-08-17
HRP20211057T1 (hr) 2021-10-01
PT2529756T (pt) 2021-07-28
EA031819B1 (ru) 2019-02-28
WO2013178812A1 (fr) 2013-12-05
RS62059B1 (sr) 2021-07-30
SI2529756T1 (sl) 2021-09-30
CL2014003216A1 (es) 2015-07-10
CA2874765A1 (fr) 2013-12-05
ES2878112T3 (es) 2021-11-18
AU2013269547B2 (en) 2018-03-15
KR20150016964A (ko) 2015-02-13
MA37664B1 (fr) 2016-11-30
SMT202100448T1 (it) 2021-09-14
EA201401346A1 (ru) 2015-04-30
EP2854858B1 (fr) 2025-12-10
DK2529756T3 (da) 2021-08-02
NZ703321A (en) 2017-01-27
EP2854858A1 (fr) 2015-04-08
PH12014502667A1 (en) 2015-02-02
MX2014014483A (es) 2015-02-24
AU2013269547A1 (en) 2015-01-22
PH12014502667B1 (en) 2020-01-22
EP2529756B1 (fr) 2021-05-19
IL235849A0 (en) 2015-01-29
MY174999A (en) 2020-06-01
LT2854858T (lt) 2026-03-10
MA37664A1 (fr) 2016-03-31
IL235849B (en) 2019-03-31
PL2854858T3 (pl) 2026-04-20
HRP20260301T1 (hr) 2026-04-10
BR112014029209A2 (pt) 2017-06-27
DK2854858T3 (da) 2026-03-09
PT2854858T (pt) 2026-03-06

Similar Documents

Publication Publication Date Title
PH12014502667A1 (en) Risperidone or paliperidone implant formulation
PH12014502668B1 (en) Paliperidone implant formulation
UA108885C2 (uk) Композиція рисперидону для ін'єкційної депо-форми
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
DK2579874T3 (da) Injicerbar, flydende sammensætning omfattende buprenorphin
EP4647126A3 (fr) Stabilisation de compositions pharmaceutiques de camptothecine
MX2017003638A (es) Microparticulas inyectables para liberacion hiper-localizada de agentes terapeuticos.
EP4650370A3 (fr) Composition pharmaceutique pour la prévention et/ou le traitement de la dermatite atopique contenant un antagoniste de l'il-31 comme principe actif
MX2015007051A (es) Diazol lactamas.
EP3162804A8 (fr) Nouveau dérivé de benzodiazépine et son utilisation
PH12017502149A1 (en) Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
WO2014119985A3 (fr) Composition pharmaceutique présentant un inhibiteur sélectif de l'enzyme phosphodiestérase sous forme de gel oral
PH12020500001A1 (en) Non-pulsatile prolonged-release betahistine oral solid compositions
IN2012CH05549A (fr)
TH159015A (th) ริสเพอริโดนหรือสูตรตำรับในการปลูกถ่ายพาลิเพอริโดน
UA106582U (uk) Спосіб профілактики післяопераційного делірію у пацієнтів похилого віку
TN2011000096A1 (en) Method for delivering a pharmaceutical composition to patient in need thereof